Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Goodwill: 2010-2025

Historic Goodwill for Anika Therapeutics (ANIK) over the last 15 years, with Sep 2025 value amounting to $8.1 million.

  • Anika Therapeutics' Goodwill rose 5.16% to $8.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.1 million, marking a year-over-year increase of 5.16%. This contributed to the annual value of $7.1 million for FY2024, which is 5.89% down from last year.
  • As of Q3 2025, Anika Therapeutics' Goodwill stood at $8.1 million, which was down 0.06% from $8.1 million recorded in Q2 2025.
  • Anika Therapeutics' Goodwill's 5-year high stood at $8.1 million during Q2 2021, with a 5-year trough of $6.7 million in Q3 2022.
  • Its 3-year average for Goodwill is $7.5 million, with a median of $7.5 million in 2023.
  • Its Goodwill has fluctuated over the past 5 years, first plummeted by 76.20% in 2021, then increased by 9.61% in 2025.
  • Anika Therapeutics' Goodwill (Quarterly) stood at $7.8 million in 2021, then decreased by 5.68% to $7.3 million in 2022, then climbed by 3.16% to $7.6 million in 2023, then decreased by 5.89% to $7.1 million in 2024, then rose by 5.16% to $8.1 million in 2025.
  • Its last three reported values are $8.1 million in Q3 2025, $8.1 million for Q2 2025, and $7.4 million during Q1 2025.